Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain (HEROIC)

Bayer

Status: Completed

Conditions: Atrial Fibrillation

Treatments: Drug: Rivaroxaban (Xarelto, BAY59-7939)

Study type: Observational

Funder types: Industry

Identifiers

NCT02262676

17671

Details and patient eligibility

About

Depict demographic and clinical features of patients with atrial fibrillation treated with rivaroxaban to prevent stroke and pulmonary embolism in routine clinical practice

Enrollment: 2,251 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients ≥ 18 years
• Patients with atrial fibrillation
• Patients in treatment with rivaroxaban for stroke prevention in atrial fibrillation at least 3 months previous to inclusion period in study

Exclusion criteria

• Patients in treatment after start of study
• Patients treated with other anticoagulant treatment

Trial design

2,251 participants in 1 patient group

Rivaroxaban

Description:

Patients with Atrial fibrillation treated with Rivaroxaban

Treatment:

Drug: Rivaroxaban (Xarelto, BAY59-7939)